Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study aims to elucidate the pathophysiological mechanisms underlying the adverse effects
associated with the use of long-acting beta-agonists (LABAs) in asthma. Participants with
mild asthma will be enrolled into a single-arm, unblinded trial in which they receive 2 weeks
of salmeterol xinafoate monotherapy, followed by a 2-week washout period, followed by 2 weeks
of salmeterol xinafoate / fluticasone propionate combination therapy. The induction of asthma
disease-relevant pro-inflammatory mediators in the airways will be measured at each stage and
correlated with relevant clinical parameters.
Phase:
Phase 4
Details
Lead Sponsor:
Imperial College London
Collaborator:
European Research Council
Treatments:
Fluticasone Fluticasone-Salmeterol Drug Combination Salmeterol Xinafoate